Hold BRK-B at 1.5% cap with FOMC hedge; reject BUY on mark-to-market contamination and peak-cycle PCP multiple
BRK-B remains HOLD at 1.5% portfolio cap despite constructive technical setup (MACD +0.40, RSI 57, intact SMAs) and valid structural elements (asymmetric forward P/E 23 vs 12.84 TTM, Q2 revenue $117.9B +19% YoY). Reject BUY on Q2 $25.7B net income contaminated by $15.9B mark-to-market reversal, PCP ~$100B valuation on single peak-cycle comparable at 26x forward 2027 EBITDA vs $37B cost basis, and $4.5B buyback at 0.4% of market cap signaling floor support not conviction. Adopt neutral analyst's three refinements: explicit FOMC hedge (20-30% trim or $500/$485 put spread for Sept expiry), relative-strength trim filter requiring underperformance to S&P/XLF on $515+ move, and PCP as upside optionality. Re-engagement on capitulation at $490-495 with >$2B/month buybacks or breakout above $511.15 on volume >5M with MACD expanding toward +0.30+.
| Position | Action |
|---|---|
| Default | Maintain current weight. Strict 1.5% portfolio cap, no exceptions. |
| Capitulation at $490-495 with buybacks accelerating to >$2B/month | Staged adds: $495 (30%), $492-494 (30%), $489-491 (40%) targeting 1.0-1.25x benchmark weight. |
| Close above $511.15 on volume >5M with MACD histogram expanding toward +0.30+ | Upgrade to Overweight. Deploy at $514, $518-522, $528-530. |
| Sell 25-33% above $515-520 ONLY if volume below 20-day average AND BRK-B underperforming S&P or XLF | Trim 25-33% of position. Hold if BRK-B is leading the market. |
BRK-B at $510.37 represents an asymmetric setup where the cash hoard is finally being deployed, interest income is at record levels, and technicals are positioned for a breakout — contradicting the bear's hold thesis.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 506.56 | bullish |
| close_50_sma | 503.85 | bullish |
| close_200_sma | 492.51 | bullish |
| rsi | 57.47 | neutral |
| macd | 0.89 | bullish |
| macds | 0.50 | bullish |
| boll_ub | 511.15 | neutral |
| atr | 6.09 | neutral |
Support: 506.56 · 503.85 · 496.4 · 492.51 | Resistance: 511.15 · 521 · 525 · 529.42 · 537.74
BRK-B is in a constructive, mildly bullish posture consolidating sideways since mid-August within a tight $495–$510 range after an ~18% rally from the August 2025 trough ($455.19) to the August 2026 peak ($537.74). The stock pressed against the upper Bollinger Band at $511.15 on September 11, with price above all three moving averages (10 EMA > 50 SMA > 200 SMA) and MACD showing a confirmed bullish crossover. RSI at 57.47 indicates neutral-to-bullish momentum with room to run before overbought territory. A confirmed daily close above $511.15 would open targets at $521, $525.44, and $529.42; failure to clear keeps the stock in a neutral $496–$511 range-trade with major structural support at the 200 SMA ($492.51). ATR of 6.09 (~1.2% of price) supports tight risk management with stops placed near the 50 SMA ($503.85).
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close above $511.15 on volume >5M with MACD histogram expanding toward +0.30+
Then: Upgrade to Overweight; deploy at $514, $518-522, $528-530
$365B in cash is a productive war chest earning 4-5% risk-free, not dead weight — generating record income and enabling aggressive buybacks
↩ rebuts: “Bear's 'cash is dead weight' argument”
EV: +2.1% to $521, +2.9% to $525, +3.7% to $529-530
Berkshire Hathaway is being priced for peak-cycle earnings at exactly the wrong moment — the bull is selling peak-rate interest income, peak-multiple PCP revaluation, and a technical setup with a 30% probability of resolving as a distribution pattern, while ignoring a 44% expected earnings decline embedded in forward estimates.
· concedes: Q2 2026 net income of $25.7B with EPS of $11.91 was genuinely strong; Interest income of ~$23B annualized is a real number generated by the T-bill portfolio; Insurance float remains a legitimate structural advantage; Berkshire is not a bad company — the bear case is about pricing, not fundamentals; Forward estimate of 44% earnings decline may be too pessimistic, assuming normalized mark-to-market, lower rates, and insurance cycle normalization all occur simultaneously
→ vs conservative: Trimming at forward P/E of 23 is flawed because the market already priced in worst-case EPS compression; Q2 2026 EPS of $11.91 vs $5.73 year-ago demolishes the declining earnings narrative, and the Precision Castparts hidden asset worth ~$100B vs $37B purchase price (2.7x appreciation) is being ignored
→ vs neutral: Waiting for breakout confirmation above $511.15 means buying at $515-$520 instead of current $510; RSI of 56 isn't stretched, trend structure is bullish, and Q2 buyback pace of $4.21B already confirms what the neutral analyst wants the market to confirm
Market Cap
$1,092.55 B
PE Ratio (TTM)
12.84
Forward PE
23.00
PEG Ratio
10.06
EPS (TTM)
$39.75
Forward EPS
$22.19
Beta
0.603
52-Week High
$537.74
52-Week Low
$464.01
Book Value (FY2025)
$717.4 B
Book Value (Q2 2026)
$747.9 B
Revenue (2025)
$410,522 M
Net Income (2025)
$66,968 M
Diluted EPS (2025)
$31.04
EBIT (2025)
$87,528 M
Net Income (2023)
$96,223 M
Net Income (2024)
$88,995 M
Operating Margin
32.6%
Profit Margin
22.3%
Return on Equity
12.1%
Return on Assets
6.0%
Total Assets (Q2 2026)
$1,263,071 M
Cash & ST Investments (Q2 2026)
$365,514 M
Long-Term Debt (Q2 2026)
$125,936 M
Tangible Book Value (Q2 2026)
$630,788 M
Current Ratio
2.89
OCF (2025)
$45,969 M
FCF (2025)
$25,042 M
CapEx (2025)
$20,927 M
Buybacks (Q2 2026)
$4,209 M
Interest Income (2025)
$23,261 M
Insurance Claims (2025)
$61.7 B
Q2 2026 Revenue
$117,885 M
Q2 2026 Net Income
$25,667 M
Q2 2026 Diluted EPS
$11.91
Strengths
Concerns
Berkshire Hathaway presents a high-quality compounder at a TTM P/E of 12.84x with fortress financials — $1.26T in assets, $365.5B in cash, and book value growing 58% over 3.5 years to $747.9B — yet faces headwinds as net income declined 30% from the 2023 peak of $96.2B to $67.0B in 2025, with the forward P/E of 23x implying further earnings pressure. The resumption of $4.21B in buybacks during Q2 2026 (after zero repurchases in all of 2025) is the most constructive signal, suggesting management views shares as undervalued at current levels; however, for new investors, the HOLD rating reflects that the stock is near its 52-week high and would offer better risk/reward on pullbacks toward the 200-day moving average of $492.
Macro: The dominant macro story is a hawkish repricing of the Federal Reserve path, with Polymarket pricing 80% probability of a 25 bp rate hike at the September 16 FOMC meeting and 90% probability of at least one hike in 2026. The 10-year Treasury yield is holding just below 5% on firm inflation data, gold has rebounded to ~$4,350/oz, and recession odds are low at 7%—indicating a soft-landing/late-cycle expansion consensus.